Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
UCN‐01 is a protein kinase inhibitor under development as a novel anticancer drug. The initial pharmacologic features in patients were not predicted from preclinical experiments. The distribution volume and the systemic clearance were much lower than those in experimental animals (mice, rats, and dogs), and the elimination half‐life was unusually long (>200 hours). The unbound fraction in human plasma was also much smaller than that in dogs, rats and mice, as was the binding of UCN‐01 to human alpha‐1 acid glycoprotein much stronger than that to human serum albumin or human γ‐globulin. The association constants for alpha‐1 acid glycoprotein and human plasma were approximately 8 × 10 8 (mol/L)−1, indicating extremely high affinity. In this review article, the authors discuss the pharmacologic features of UCN‐01 across species and provide a perspective on how this information could be applied prospectively to the future development of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Self-citationKawakami, K., Futami, H., Takahara, J., & Yamaguchi, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0310 · Cited by 120
Akinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685833 · Cited by 118
Cited by
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Sánchez, C., Méndez, C., & Salas, J. A. (2006) · Nat. Prod. Rep. · doi:10.1039/b601930g · Cited by 407
Metadata
- Authors
- Fuse, E., Kuwabara, T., Sparreboom, A., Sausville, E. A., & Figg, W. D.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 45
- Issue
- 4
- Pages
- 394-403
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2080758225
- Cited by
- 110
- References
- 3
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology. https://app.cochat.ai/papers/10.1177/0091270005274549
- The paper
- Fuse, E., Kuwabara, T., Sparreboom, A., Sausville, E. A., & Figg, W. D. (2005). Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270005274549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.